Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 6Bortezomib 6tanespimycin 5romidepsin 5Vorinostat 5Tacrolimus 5Magnetic Resonance Spectroscopy 5Gemcitabine 5fludarabine 4Radiotherapy 4Lenalidomide 4Etoposide 4belinostat 3Whole-Body Irradiation 3Specimen Handling 3Nivolumab 3Mycophenolic Acid 3Irinotecan 3Doxorubicin 3Dasatinib 3Brentuximab Vedotin 3Biopsy 3Bendamustine Hydrochloride 3sodium-iodide symporter 2pembrolizumab 2nelarabine 2mogamulizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mycosis Fungoides × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡